The SGLT2 inhibitor eliminates excess blood glucose through excretion by the kidneys and may lead to ketoacidosis, in a subset of individuals with diabetes, even though blood glucose is well controlled (i.e., euglycemic ketoacidosis).61, 62, 63, 64. Here, SLC5A2 is linked to diabetes mellitus.